Get started
Author

Sriram Ravichandran

Observed names: Ravichandran, Sriram, S Ravichandran, S. Ravichandran
Observed institutions: University College Hospital, Royal Free London NHS Foundation Trust, Tata Memorial Hospital, The Royal Free Hospital, Barnet Hospital, Tata Medical Center, University College London
ORCID: 0000-0001-5650-0088
Observed ORCID: 0000-0001-5650-0088
OpenAlex ID: A5067542994
Epidemiologic and Survival Trends in Amyloidosis, 1987–2019
2020 · Sriram Ravichandran, Helen J. Lachmann, et al. · New England Journal of Medicine · 159
PDF
Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment
2022 · Ana Martinez-Naharro, Rishi Patel, et al. · European Heart Journal · 118
PDF
Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis
2021 · Oliver C Cohen, Andreia Ismael, et al. · European Heart Journal · 113
Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis
2023 · Muhammad Umaid Rauf, Philip N Hawkins, et al. · European Heart Journal · 99
PDF
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis
2021 · Giovanni Palladini, Bruno Paiva, et al. · Blood Cancer Journal · 76
PDF
Characteristics and natural history of early-stage cardiac transthyretin amyloidosis
2022 · Steven Law, Melanie Bezard, et al. · European Heart Journal · 66
PDF
The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018
2023 · Giovanni Palladini, Stefan Schönland, et al. · Blood Cancer Journal · 57
PDF
Disease Progression in Cardiac Transthyretin Amyloidosis is Indicated by Serial Calculation of National Amyloidosis Centre Transthyretin Amyloidosis Stage
2020 · Steven Law, Aviva Petrie, et al. · ESC Heart Failure · 46
PDF
Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis
2024 · Joshua Bomsztyk, Sriram Ravichandran, et al. · Blood · 38
PDF
Redefining Cardiac Involvement and Targets of Treatment in Systemic Immunoglobulin AL Amyloidosis
2024 · Aldostefano Porcari, Ambra Masi, et al. · JAMA Cardiology · 35
Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein
2023 · Vinit Upasani, Katie Townsend, et al. · Clinical Infectious Diseases · 34
PDF
Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib
2021 · Sriram Ravichandran, Oliver C. Cohen, et al. · Blood Cancer Journal · 34
PDF
Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy
2021 · Steven Law, Aviva Petrie, et al. · Heart · 28
PDF
Cardiac transplantation in transthyretin amyloid cardiomyopathy: Outcomes from three decades of tertiary center experience
2023 · Yousuf Razvi, Aldostefano Porcari, et al. · Frontiers in Cardiovascular Medicine · 24
The experience of hereditary apolipoprotein A-I amyloidosis at the UK National Amyloidosis Centre
2022 · Oliver C. Cohen, Iona J. Blakeney, et al. · Amyloid · 23
Prognostic importance of the 6 min walk test in light chain (AL) amyloidosis
2022 · Oliver C Cohen, Ananth Sathyanath, et al. · Heart · 17
PDF
Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis
2020 · Oliver C. Cohen, Maximillian H. Brodermann, et al. · Amyloid · 15
PDF
Limited utility of Mayo 2012 cardiac staging system for risk stratification of patients with advanced cardiac AL amyloidosis - analysis of a uniformly treated cohort of 1,275 patients
2024 · Jahanzaib Khwaja, Sriram Ravichandran, et al. · Haematologica · 14
PDF
New Validated Staging System for Light Chain (AL) Amyloidosis With Stage IIIC Defining Ultra-Poor Risk: AL International Staging System
2025 · Jahanzaib Khwaja, Amy A. Kirkwood, et al. · Journal of Clinical Oncology · 12
PDF
A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis
2023 · Sriram Ravichandran, Andrew Hall, et al. · Amyloid · 9
PDF
Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients
2021 · Giovanni Palladini, Stefan Schönland, et al. · Blood · 9
The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis
2020 · Oliver C. Cohen, Steven Law, et al. · Blood Cancer Journal · 9
PDF
NK/T Cell Lymphoma: A Tertiary Centre Experience
2016 · Neeraj Arora, Arpan Mehta, et al. · Indian Journal of Hematology and Blood Transfusion · 9
PDF
A UK consensus algorithm for early treatment modification in newly diagnosed systemic light‐chain amyloidosis
2022 · Sriram Ravichandran, Shameem Mahmood, et al. · British Journal of Haematology · 8
Outcomes of daratumumab–bortezomib–thalidomide–dexamethasone in treatment‐naive systemic AL amyloidosis
2025 · Jahanzaib Khwaja, Sriram Ravichandran, et al. · British Journal of Haematology · 7
PDF
Works count: 71
Citation count: 1,122
H-index: 16
I10-index: 19
Year
Topic
Type